Deletion of arginase 2 attenuates neuroinflammation in an experimental model of optic neuritis

Amritha A. Candadai, Fang Liu, Abdelrahman Y. Fouda, Moaddey Alfarhan, Chithra D. Palani, Zhimin Xu, Ruth B. Caldwell, S. Priya Narayanan

1 Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, United States of America, 2 Culver Vision Discovery Institute, Augusta University, Augusta, GA, United States of America, 3 Charlie Norwood VA Medical Center, Augusta, GA, United States of America, 4 Vascular Biology Center, Augusta University, Augusta, GA, United States of America, 5 Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA, United States of America

☯ These authors contributed equally to this work.

*pnarayanan@augusta.edu, priya.narayanan@uga.edu

Abstract

Vision impairment due to optic neuritis (ON) is one of the major clinical presentations in Multiple Sclerosis (MS) and is characterized by inflammation and degeneration of the optic nerve and retina. Currently available treatments are only partially effective and have a limited impact on the neuroinflammatory pathology of the disease. A recent study from our laboratory highlighted the beneficial effect of arginase 2 (A2) deletion in suppressing retinal neurodegeneration and inflammation in an experimental model of MS. Utilizing the same model, the present study investigated the impact of A2 deficiency on MS-induced optic neuritis. Experimental autoimmune encephalomyelitis (EAE) was induced in wild-type (WT) and A2 knockout (A2−/−) mice. EAE-induced cellular infiltration, as well as activation of microglia and macrophages, were reduced in A2−/− optic nerves. Axonal degeneration and demyelination seen in EAE optic nerves were observed to be reduced with A2 deletion. Further, the lack of A2 significantly ameliorated astrogliosis induced by EAE. In conclusion, our findings demonstrate a critical involvement of arginase 2 in mediating neuroinflammation in optic neuritis and suggest the potential of A2 blockade as a targeted therapy for MS-induced optic neuritis.

Introduction

Multiple Sclerosis (MS) is a chronic, autoimmune, inflammatory, and neurodegenerative disease of the central nervous system (CNS) [1, 2]. This disorder affects approximately 400,000 people in the United States and 2.1 million people worldwide [3], with a higher incidence rate in women [4, 5]. Visual dysfunction due to optic neuritis is a common complication faced by approximately 20% of MS patients [6, 7]. Optic neuritis caused by inflammation of the optic nerve is characterized by thinning of the nerve fiber layer, retinal ganglion cell (RGC) loss, and
Symptomatically, a patient experiences unilateral optic neuritis that may present with acute pain in the retroorbital and/or periorbital regions, blurred vision, color vision deficits, and ultimate vision loss [12]. Current medications available for MS-induced optic neuritis such as i.v. methylprednisolone or other oral steroids are only partially effective [13]. They provide symptomatic benefits but have limited impact on the neuroinflammatory pathology of the disease. An agent with anti-inflammatory and neuroprotective effects may offer advantages over existing therapies in reducing MS disability.

Experimental autoimmune encephalomyelitis (EAE) is an established experimental murine model for MS studies [14]. Previous studies have demonstrated that EAE mice develop retinal damage, RGC loss, and optic neuritis mediated by an inflammatory cascade and neurodegeneration [15–18]. Oxidative stress is a key mechanism implicated in MS and EAE progression [19, 20]. This pathological mechanism may be driven by several pathways such as activation of microglia/macrophages and altered nitric oxide synthase (NOS) that contribute to the generation of reactive species like reactive oxygen species (ROS), reactive nitrogen species (RNS). Enhanced expression of inducible NOS (iNOS) and activated microglia were found in MS lesions and EAE animals [21–23]. Increased arginase activity also correlated with iNOS expression in the brain and spinal cord of EAE animals [24].

A recently published study from our laboratory demonstrated a retinal protective effect of Arginase 2 (A2) deletion in the EAE model [25]. A significant increase in neuronal survival was accompanied by a reduction in the expression of proinflammatory molecules and decreased glial activation in the retina. EAE-induced motor deficits were also decreased in response to A2 deletion. The goal of our current study is to further characterize the protective effects of A2 deletion in EAE-induced optic nerve degeneration. Utilizing a combination of immunofluorescence staining and imaging techniques, this study investigated the impact of A2 deletion on EAE-induced inflammatory changes and axonal pathology in the optic nerve.

**Materials and methods**

**Animals and induction of EAE**

Wild-type (WT) and arginase 2 knockout (A2−/−) mice on a C57BL/6J background were maintained in our animal facility and used for this study. This study was conducted in strict accordance with the ‘ARVO Statement for the Use of Animals in Ophthalmic and Vision Research’. All procedures were performed according to the approved institutional guidelines (Animal Welfare Assurance no. A3307–01) and adhered to the Public Health Service Policy on Humane Care and Use of Laboratory Animals (revised July 2017). The protocol was approved by the Institutional Animal Care and Use Committee the Augusta University (Protocol Number: 2016–0823). All efforts were made to assure the minimum possible suffering during experimental procedures. Mice were euthanized by overdose with a ketamine/xylazine cocktail. The EAE induction kit (Hooke Laboratories, Lawrence, MA, cat. no. EK-2110) was utilized for chronic EAE induction [25]. On day 0, mice in the EAE group received subcutaneous injections of myelin oligodendrocyte glycoprotein (MOG35–55) peptide emulsion (200 μL, 200 μg/mouse) along with Complete Freund’s Adjuvant (CFA, killed *M. tuberculosis* H37Ra, 400 μg/μL). Injections of pertussis toxin (PTX, 100 ng in 50 μL PBS) were administered intraperitoneally to each mouse 2h post-immunization on day 0 and day 1. The control group received the same treatment excluding the peptide injection. Four groups were included in the study; a) **WT control**: WT mice immunized with CFA alone and PTX, b) **WT EAE**: WT mice immunized with MOG in CFA and PTX, c) **A2−/− control**: A2−/− mice immunized with CFA and PTX, and d) **A2−/− EAE**: A2−/− mice immunized with MOG in CFA and PTX. Neurological deficits were assessed daily using a blinded scoring method according to the conventional...
grading system as described in our previous study [25]. Briefly, 0, no disease; 1, complete loss of tail tonicity; 2, partial hind limb paralysis (uneven gate of hind limb); 3, complete hind limb paralysis; 4, complete hind and forelimb paralysis; and 5, moribund or dead. Animals displaying paralysis on four limbs and/or weight loss more than 15% were sacrificed. Soft food was provided in the cage for paralyzed mice.

**Optic nerve isolation and sectioning**

Following 60 days post-induction, mice were euthanized by overdose with ketamine/xylazine cocktail, and optic nerves were removed, post-fixed in 4% paraformaldehyde, cryoprotected with 30% sucrose, embedded in optimum cutting temperature (OCT) compound and stored at −80°C. Longitudinal sections of the optic nerve (10 μm) were prepared using a cryostat and mounted on gelatin-coated glass slides. Sections were preserved at −80°C for immunostaining.

**Hematoxylin and Eosin (H&E) staining and analysis of cellular infiltration**

Optic nerve sections were subjected to H&E staining at Augusta University histology core. Images were taken using Zeiss Axioplan 2 microscope and the analysis was performed using the "point tool" function of NIH ImageJ software (National Institutes of Health, USA).

**Immunofluorescence staining of optic nerve**

Optic nerve cryo-sections were acclimatized to room temperature and rehydrated using wash buffer 1X phosphate buffered saline (PBS). Excess buffer was drained, and tissue sections were surrounded with a hydrophobic barrier using ImmEdge Pen (Vector Laboratories). Permeabilization was achieved using 1% Triton X-100 in PBS for 10 mins, followed by a PBS wash cycle and blocking (10% donkey serum for 1h) at room temperature. Sections were washed with PBS and incubated with respective primary antibodies (Table 1) overnight. The next morning, sections were washed, followed by incubation with the appropriate secondary antibodies (Table 1) for 2h. Sections were washed (1X PBS), dried, and covered with mounting medium for imaging.

**Imaging and quantification**

Images were captured using Keyence fluorescence microscope (BZ-X800, Itasca, Illinois, USA) and/or confocal microscope (LSM 780; Carl Zeiss, Thornwood, NY, USA). Staining appeared

| Antibody used | Catalogue No. | Company | Dilution |
|---------------|--------------|---------|----------|
| Arginase 1    | 610709       | BD Biosciences, San Jose, CA, USA | 1:200    |
| CD16/32       | 553142       | BD Biosciences, San Jose, CA, USA | 1:100    |
| CD 86         | ab213044     | Abcam, Cambridge, MA, USA | 1:500    |
| F4/80         | ab6640       | Abcam, Cambridge, MA, USA | 1:200    |
| GFAP          | Z033429-2    | Dako, Carpinteria, CA, USA | 1:200    |
| Iba1          | 019–19741    | Wako, Richmond, VA, USA | 1:200    |
| MBP           | MAB386       | MilliporeSigma, St. Louis, MO, USA | 1:100    |
| SMI 32        | 801701       | BioLegend, San Diego, CA, USA | 1:200    |

Secondary antibody used

| Antibody used | Catalogue No. | Company | Dilution |
|---------------|--------------|---------|----------|
| Donkey anti-Rabbit IgG (H+L) Polyclonal Secondary Antibody, Alexa Fluor 488 | A21206 | Invitrogen™, Waltham, MA, USA | 1:500    |
| Donkey anti-Rat IgG (H+L) secondary Antibody, Alexa Fluor 488 | A21208 | Invitrogen™, Waltham, MA, USA | 1:500    |
| Donkey anti-Mouse IgG (H+L) Polyclonal, Secondary Antibody, Alexa Fluor 555 | A31570 | Invitrogen™, Waltham, MA, USA | 1:500    |

https://doi.org/10.1371/journal.pone.0247901.001
homogenous throughout the optic nerve unless stated otherwise in the results. For quantification, a minimum of two sections per optic nerve were utilized for each antibody. A minimum of three non-overlapping fields per section were imaged using confocal microscope for quantification, resulting in a minimum of 6 images per mouse per antibody. A minimum of 5 animals per group were included for each study.

Quantification Iba1 positive cells based on morphology was performed using ImageJ software. Briefly, 40X confocal images (maximum intensity projection) were converted to 8-bit grey scale and a threshold was applied to track the cells. The cells with enlarged soma size were selected and quantified using the “Analyze particle” function (pixel size: 500-infinity and circularity: 0.10–1.00). Quantification of F4/80 (EGF-like module containing mucin-like hormone receptor-like 1), CD 86, A1 and CD 16/32 was performed on 40X images using the “point tool” function of ImageJ software. Fluorescence intensity was measured as integrated density using ImageJ software, and the mean values were calculated and expressed as the fluorescence intensity per field of view for each marker used. The area of fields measured per marker (SMI 32 (Neurofilament H (non-phosphorylated), MBP (Myelin Basic Protein) and GFAP (Glial Fibrillary Acidic Protein)) was maintained uniformly throughout all groups and values were normalized relative to the percentage of WT control group.

**Statistical analysis**

All statistical analyses were performed with GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA). Outliers were eliminated using Grubbs’ outliers test at a significance level of 0.05. Two-way ANOVA followed by Tukey’s multiple comparisons test was employed to analyze the groups. A p < 0.05 was defined as statistically significant. Results are presented as Mean ± SEM.

**Results**

**A2 deletion reduced EAE-induced cellular infiltration in the optic nerve**

Histological analysis of optic nerve sections demonstrated increased cellular infiltration in the EAE optic nerves (Fig 1). WT EAE optic nerve sections showed hypercellularity compared to WT controls (Fig 1A and 1B). However, EAE-induced cellular infiltration was markedly reduced in the A2−/− optic nerve samples (Fig 2C). Magnified images (Fig 1E–1H) show increased clusters of infiltrated cells in the WT EAE optic nerve compared to the A2−/− EAE and the control samples. Quantification of the infiltrated cells presented in Fig 1I demonstrated a significant reduction in infiltrated cells in the A2−/− EAE optic nerves compared to WT EAE and WT controls. These results indicate that A2 deletion reduces EAE-induced cellular infiltration in the optic nerve.

Fig 1. Changes in EAE-induced cellular infiltration in the optic nerve. A–D) Representative images of H&E stained sections from control and EAE optic nerves. Increased infiltration was evident in WT EAE sections, while A2 deletion markedly reduced this effect. E–H) High magnification images of boxed regions demonstrate EAE-induced cellular infiltration. Arrows indicate clusters of infiltrated cells. I) Quantification of infiltrated cells using ImageJ. Data are presented as Mean ± SEM. *p<0.01 WT EAE vs WT Con and *p<0.05 A2−/− EAE vs WT EAE. Number of animals used: 8 (WT Control); 12 (WT EAE); 9 (A2−/− EAE); 7 (A2−/− Control). Representative images are presented. Scale bar 50 μm.

https://doi.org/10.1371/journal.pone.0247901.g001
two-fold increase in the WT EAE optic nerve compared to the WT control. EAE optic nerves from A2−/− mice showed significantly reduced levels of cellular infiltration (Fig 1I).

**EAE-induced microglial/macrophage activation is reduced by A2 deletion**

Immunofluorescence staining using Iba1 (Ionized calcium-binding adaptor molecule 1) and F4/80 (EGF-like module-containing mucin-like hormone receptor-like 1) antibodies were utilized to demonstrate activation of microglia and macrophages in response to EAE (Figs 2 and 3). Morphologically, resting microglia appear elongated with well-defined processes and activated microglia show a more compact ameboid appearance [26]. As shown in Fig 2A, 2B, 2E and 2F, WT EAE optic nerves demonstrated increased Iba1 positive cells with activated morphology compared to the WT control group. Deletion of A2 ameliorated these EAE-induced changes in the optic nerve (Fig 2C and 2G). Quantification of the Iba1 positive cells with activated morphology (i.e. enlarged cell body) (Fig 2I) shows a significant increase in the WT EAE group as compared with the WT Control (#p<0.01), and this change was significantly prevented in the A2−/−EAE group (*p<0.01). A2−/− control optic nerves did not show any noticeable alterations in the morphology of Iba1 positive cell as compared with the WT control nerves.

F4/80 (EGF-like module-containing mucin-like hormone receptor-like 1) is a marker for macrophagic/microglia cells [27, 28]. In our study, immunostaining of the optic nerve sections was used to demonstrate EAE-induced changes using F4/80 positive macrophage/microglia cells. WT EAE optic nerves demonstrated an increased level of F4/80 cells in comparison to WT Con (Fig 3A, 3B, 3E and 3F). EAE-induced increase in F4/80 positive cells was downregulated in response to A2 deletion (Fig 3C and 3G). These observations are supported by the quantification studies indicating a significant increase in F4/80 positive cells (Fig 3I) in WT EAE versus WT Con group (*p<0.01), which was significantly suppressed in the A2−/−EAE group (**p<0.01).

Macrophages are known to exist in two major types, the pro-inflammatory M1 and anti-inflammatory M2 [29] and can transition between the phenotypes depending on the microenvironment [30]. Further characterization using markers for M1 and/or M2 phenotypes demonstrated upregulation in the M1-like macrophage phenotype (studied by CD16/CD32 and CD86 markers) in WT EAE optic nerve compared to WT Control (Fig 3J and 3K, versus O...
and P, respectively). This alteration was prevented in the A2−/− EAE samples (Fig 3L and 3Q). Quantification studies show that the number of cells positive for CD16/CD32 (Fig 3N) and CD86 (Fig 3S) was significantly increased in WT EAE optic nerves compared to the WT control group (#p < 0.01), while these changes were prevented in the A2−/− EAE group (ÿp < 0.05). Immunostaining experiments using anti-Arginase 1, an M2 marker, did not show any significant changes across the groups (T–W). Number of animals used: 8 (WT Control); 12 (WT EAE); 9 (A2−/− EAE); 7 (A2−/− Control). Representative images are presented. Scale bar 50 μm. Data are presented as Mean ± SEM. #p < 0.01 WT EAE vs WT Con and # p < 0.01 A2−/− EAE vs WT EAE.

https://doi.org/10.1371/journal.pone.0247901.g003

Evaluation of EAE-induced axonal degeneration and demyelination

Axonal degeneration is a characteristic feature of EAE. Immunolabeling for SMI 32 (marker of neurofilament proteins) was employed to assess the axonal changes in response to EAE. The SMI 32 antibody has shown to label RGC cell bodies and axons [31–33]. Morphological changes suggesting degeneration/disorganization of axons were evident in the EAE optic nerves. Immunolabeling of SM132 in optic nerves from the control group demonstrated long fibers arranged in parallel, while degenerative changes and structural distortions such as shorter and transected axons and presence of spheroids were observed EAE optic nerves (Fig 4A–4D). These alterations were reduced in the optic nerves lacking A2. Quantification data presented in Fig 4E demonstrate the significantly reduced levels of SM132-positive
neurofilaments in WT EAE optic nerve compared to WT control ("p < 0.01), however, the improvement observed in A2−/- EAE was not statistically significant with WT EAE group.

Along with the degeneration of axons, demyelination is another major characteristic seen in MS and EAE. Immunofluorescence using myelin basic protein (MBP) was used to analyze the extent of demyelination in the EAE optic nerves (Fig 5). WT EAE optic nerves showed greater myelin loss (studied by reduced MBP levels) when compared with WT control nerves (Fig 5A, 5B, 5E and 5F). This loss was suppressed in A2 deficient EAE optic nerves (Fig 5C and 5G) suggesting reduced demyelination in response to EAE. Quantification data presented in Fig 5I demonstrate the significantly reduced MBP (fluorescence intensity) levels in WT EAE optic nerve compared to WT con ("p < 0.01), while this decrease was significantly abrogated in A2−/- EAE optic nerves ("p < 0.05).

EAE-induced astroglisis was reduced in A2−/- optic nerve

Changes in the extent of astroglisis were evaluated using GFAP (Giall Fibrillary Acidic Protein) antibody. EAE induction resulted in increased levels of reactive astrocytes as shown by increased immunoreactivity for GFAP in the WT EAE optic nerves compared to WT Con optic nerves (Fig 6A, 6B, 6E and 6F). This was largely prevented by A2 deletion (Fig 6C and 6G). Quantification of GFAP intensity confirmed the significant increase in WT EAE as compared with WT Con ("p < 0.01). This increase was suppressed with A2 deletion in A2−/- EAE in comparison to WT EAE ("p < 0.05) (Fig 6I).

Discussion

MS pathogenesis is dominated by the combined action of inflammation and demyelination leading to axonal degeneration. In the present study, we investigated the impact of Arginase 2
A2 deletion in the degeneration of the EAE optic nerve. To the best of our knowledge, this is the first report determining the impact of A2 deletion in regulating EAE-induced inflammation, axonal damage, and myelin loss in the optic nerve. As described in our previous study [25], EAE-induced motor deficits were milder in A2−/− EAE mice as demonstrated by the lower clinical scores throughout the induction period. The initial signs of paralysis indicated by the loss of tail tonicity started at day 9 in WT EAE mice, and the clinical signs of EAE increased gradually. In A2−/− mice induced with EAE, appearance of the initial signs of paralysis was delayed (beginning at day 11) and the clinical scores were significantly lower compared to WT EAE mice [25].

MS-induced optic neuritis is characterized by inflammation of the optic nerve along with axonal degeneration and RGC loss [8–11]. Infiltration of inflammatory cells into the EAE optic nerve has been reported by several studies [15, 34–36]. These mainly include infiltration of T cells (CD4+), and macrophages into the CNS during EAE progression [15, 35, 37–39]. Previous studies have shown increased arginase activity, NO production, and methylated arginine derivatives in the EAE brain and spinal cord tissues suggesting their strong involvement in the inflammatory and neurodegenerative pathways of disease progression [24, 40, 41]. Both A1 and A2 isoforms of arginase are also known to be expressed in the brain and retina [42]. Previous studies from our group have demonstrated that A2 deletion reduces retinal inflammation in EAE and other models of retinal injury [43–45]. Disruption of the blood-brain barrier (BBB) and subsequent cellular infiltration into the CNS is well-established in MS pathology. This process is characterized by the surge of T lymphocytes and monocyte-derived macrophages that cause demyelinating CNS lesions [46, 47]. Microglia and macrophages are known to interact with T-cells and modulate their function in EAE [48]. Likewise, microglial activation and macrophage/T-cell influx have been validated in the optic nerve in previous EAE studies [49, 50]. Our studies show a reduction in cellular infiltration and cluster formation in A2−/− EAE optic nerves.

Previous studies in the EAE model have shown microglial as well as macrophagic autoimmune response and subsequent activation of the inflammatory cascade in the spinal cord, brain, and optic nerve [16, 51]. Consistent with our previous observations in the retina of EAE mice [25], our current study showed that EAE-induced inflammatory responses were significantly reduced in the optic nerves of EAE mice lacking the A2 gene. This was further...
confirmed by our findings that demonstrated reduced Iba1+ and F4/80+ cells in A2−/− EAE optic nerves. Our results further showed that the presence of M1-like pro-inflammatory macrophages are markedly reduced in response to A2 deletion. The definite roles of macrophage populations remain controversial and are yet to be elucidated. Cells of the monocyte/macrophage lineage can shift between activation stages in response to cues in the local microenvironment [52, 53]. Arginase 1 (A1) is a marker for the M2-like pro-reparative macrophage phenotype [54–56], and our previous study has shown an increased A1 mRNA level in the A2−/− EAE retina compared to the WT EAE retina [25]. However, no significant changes were observed in A1 positive cells in the EAE optic nerves at 60 days. Previous studies showed A1 to be strongly upregulated in the spinal cord of EAE models [57, 58]. Others have demonstrated the upregulation of A1 positive myeloid cells during EAE progression with inverse correlation with disease severity [59–61]. In the present study, we investigated A1 positive cells at a later time point (60 days post induction) and that could be the reason for not observing any differences.

Several studies have demonstrated axonal damage and demyelination in EAE-induced optic neuritis [15, 36, 62, 63]. Activated microglia and infiltrated macrophages are targeted towards demyelination and axonal injury. Disrupted axonal deposits and swelling of mitochondria and other organelles is a distinctive morphological feature of injured axons [63–65]. In the present study, axonal damage was studied using immunolabeling with an SMI 32 antibody (which reacts with a nonphosphorylated epitope in neurofilament H of most mammalian species). SMI 32 labels neuronal cell bodies, dendrites, and some thick axons in the central and peripheral nervous systems (manufacturer’s datasheet). In the retina, this antibody has been shown to immunolabel the cytoskeleton of medium and large ganglion cells, as well as ganglion cell axons of mouse, rat and cat retina [66–68]. SMI 32 has been used a marker to study abnormalities in the brain and spinal cord in experimental models of MS [69–72], as non-phosphorylated neurofilaments are a predominant feature in damaged axons. However, in our study the fluorescent intensity of SMI 32 immunostaining was reduced in the EAE optic nerves. This could be due to differences in the antibody we used or the time point of our analysis as compared with the previous studies. A recent study (using the same antibody resource) reported an increase in SMI 32 in EAE optic nerves at an early stage of disease (16 days post induction (DPI)), while the expression was significantly downregulated at a later stage (42 DPI) of EAE progression [17]. These results are consistent with our observation where SMI 32 was decreased in EAE optic nerves at 60 DPI. Some authors have suggested that the changes in SMI 32 levels result from impaired axonal transport at the peak of EAE followed by axonal loss at later stages of the disease [17]. An earlier study also reported increased SMI 32 levels in the EAE optic nerves at 14 days after the induction [73]. Our future studies will address the time dependent changes in SMI 32 expression and axonal degeneration in the WT and A2 deficient EAE optic nerves. The protective effects demonstrated by A2−/− optic nerves could be due to cumulative anti-inflammatory and neuroprotective effects mediated by A2 deletion. A previous study has demonstrated that A1 can promote axonal regeneration via increased spermidine synthesis [74]. A marked reduction of EAE-induced myelin loss in spinal cord lesions by A2 deletion was revealed by Choudry et al. [75]. In our study, we observed that damage to the axonal filaments and myelin fibers in EAE optic nerves was limited in the A2−/− mice. Our future studies will investigate the integrity of myelin sheath using electron microscopy.

Astroglial hypertrophy is an important indication of tissue injury and could be resulting from disruption of the astrocyte-oligodendrocyte network. Physiologically, astrocytes maintain homeostasis of a healthy CNS by upholding a constant anti-inflammatory and protective environment [76, 77]. However, injury-induced reactive astrocytes are a source of increased reactive oxygen species (ROS) formation and pro-inflammatory cytokines [78]. Previous
reports from our group have demonstrated that lack of A2 reduced activation of Müller glial cells in retinal injury models [43, 44]. Our study reveals significantly reduced gliosis in the A2−/− EAE optic nerve, which further confirms the protective effects mediated by A2 deletion in the CNS and its potential as a therapeutic target. However, one limitation is the lack of a specific inhibitor for arginase 2. Hence, proper design of more selective and cell-targeted inhibitors is needed to validate A2 as a therapy for the disease.

Overall, our present study shows the impact of A2 deletion in preserving neuroimmune functions in the retina and optic nerve. Studies from other laboratories have demonstrated the involvement of arginase signaling in MOG-induced EAE mouse models [56, 59, 75, 79]. Involvement of A1 in EAE models is previously reported. Levels of A1 mRNA are elevated in spinal cord samples from EAE mice [61]. A1 positive myeloid cells have been found to be upregulated during the progression of EAE [59–61] and their presence was shown to be inversely correlated with the severity of disease with greater expression at the earlier stage [61, 80]. These A1 expressing cells, especially the myeloid-derived suppressor cells are hypothesized to inhibit T-cell activation and therefore, may dampen the autoimmune-mediated demyelination in EAE [81, 82]. A report by Xu et al provided data showing a less severe EAE phenotype in mice treated with the arginase inhibitor, amino-6-boronohexanoic acid (ABH) [57]. However, ABH inhibits both arginase isoforms and may be protective due to inhibition of A2. A possible interaction between the two arginase isoforms in EAE is unknown and yet to be elucidated. Oxidative stress mediated by the generation of ROS/RNS and activation of inflammatory cascade evidently contributes towards MS as well as EAE pathogenesis [21–23]. Increased activity of iNOS and arginase levels in EAE animals also demonstrates their involvement [24]. Correspondingly, our group has previously shown that A2 deletion is protective against neuronal apoptosis by suppressing polyamine oxidation via the ornithine/polyamine pathway [44]. These findings portray the significance of arginase and associated signaling molecules (NOS, polyamines, ROS, RNS) in the neuronal milieu.

Conclusion
The present study highlights the impact of arginase 2 deficiency in reducing cellular infiltrates, attenuating the activation of microglia and macrophages, mitigating axonal and myelin damage, and reducing astrogliosis in an experimental model of optic neuritis. Therefore, arginase 2 deficiency or blockade may positively contribute towards targeted neuroprotection in MS-induced optic neuritis.

Acknowledgments
Authors thank Ms. Penny Roon and Ms. Libby Perry (Electron microscopy and histology core, Augusta University) for their help in the completion of H&E staining of optic nerve sections.

Author Contributions
Conceptualization: S. Priya Narayanan.
Formal analysis: Amritha A. Candadai, Fang Liu, Moaddey Alfarhan.
Funding acquisition: S. Priya Narayanan.
Investigation: Amritha A. Candadai, Fang Liu, Abdelrahman Y. Fouda, S. Priya Narayanan.
Methodology: Amritha A. Candadai, Fang Liu, Abdelrahman Y. Fouda, Moaddey Alfarhan, Chithra D. Palani, Zhimin Xu.
Project administration: S. Priya Narayanan.
Resources: Ruth B. Caldwell, S. Priya Narayanan.

Supervision: Abdelrahman Y. Fouda, Ruth B. Caldwell, S. Priya Narayanan.

Visualization: Fang Liu.

Writing – original draft: Amritha A. Candadai.

Writing – review & editing: Fang Liu, Abdelrahman Y. Fouda, Moaddey Alfarhan, Ruth B. Caldwell, S. Priya Narayanan.

References

1. Filippi M, Rocca MA. Multiple sclerosis: new measures to monitor the disease. Lancet Neurol. 2013; 12 (1):12–3. Epub 2012/12/15. https://doi.org/10.1016/S1474-4422(12)70288-0 PMID: 23237892.

2. Lassmann H, van Horsen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011; 585(23):3715–23. Epub 2011/08/23. https://doi.org/10.1016/j.febslet.2011.08.004 PMID: 21854776.

3. Zwibel HL, Smrta J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011; 17 Suppl 5 Improving:S139–45. Epub 2011/07/27. PMID: 21761952.

4. Alonso A, Hernández A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008; 71(2):129–35. Epub 2008/07/09. https://doi.org/10.1227/01.wnl.0000316802.35974.34 PMID: 18606967; PubMed Central PMCID: PMC4109189.

5. Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhan M, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013; 13:128. Epub 2013/09/28. https://doi.org/10.1186/1471-2377-13-128 PMID: 24070256; PubMed Central PMCID: PMC3856596.

6. Burman J, Raininko R, Fagius J. Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurol Scand. 2011; 123(3):207–10. Epub 2010/06/24. https://doi.org/10.1111/j.1600-0404.2010.01388.x PMID: 20569226.

7. Sørensen TL, Frederiksen JL, Brannum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology. 1999; 53(3):473–8. Epub 1999/08/17. https://doi.org/10.1212/wnl.53.3.473 PMID: 10449106.

8. Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005; 58(3):383–91. Epub 2005/08/03. https://doi.org/10.1002/ana.20575 PMID: 16075460.

9. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012; 119(6):1250–7. Epub 2012/03/01. https://doi.org/10.1016/j.jophtha.2011.11.032 PMID: 22365058; PubMed Central PMCID: PMC3631566.

10. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease. Semin Ophthalmol. 2003; 18(2):50–7. Epub 2003/10/21. https://doi.org/10.1076/sooph.18.2.50.15855 PMID: 14566623.

11. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol. 2008; 4(12):664–75. Epub 2008/12/02. https://doi.org/10.1038/ncpneuro0950 PMID: 19043412; PubMed Central PMCID: PMC2743162.

12. Pau D, Al Zubidi N, Yalamanchili S, Plant GT, Lee AG. Optic neuritis. Eye (Lond). 2011; 25(7):833–42. Epub 2011/04/30. https://doi.org/10.1038/eye.2011.81 PMID: 21527960; PubMed Central PMCID: PMC3178158.

13. Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, et al. Re-evaluating the treatment of acute optic neuritis. J Neurol Neurosurg Psychiatry. 2015; 86(7):799–808. Epub 2014/10/31. https://doi.org/10.1136/jnnp-2014-308185 PMID: 25355373; PubMed Central PMCID: PMC4414747.

14. Farooqi N, Gran B, Constantinescu CS. Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis? J Neurochem. 2010; 115(4):829–44. Epub 2010/09/03. https://doi.org/10.1111/j.1471-4159.2010.06982.x PMID: 20867399.

15. Wilmes AT, Reineier S, Kühn S, Pedreturcia X, Petrikowski S, Faisner S, et al. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. J Neuroinflammation.
16. Horstmann L, Kuehn S, Pedretiturria X, Haak K, Pfarrer C, Dick HB, et al. Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016; 298:32–41. Epub 2016/09/10. https://doi.org/10.1016/j.jneuroim.2016.06.008 PMID: 27609273.

17. Jin J, Smith MD, Kersbergen CJ, Kam TI, Viswanathan M, Martin K, et al. Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuro-pathol Commun. 2019; 7(1):125. Epub 2019/08/02. https://doi.org/10.1186/s40478-019-0767-6 PMID: 31366377; PubMed Central PMCID: PMC6670238.

18. Nishioka C, Liang HF, Barsamian B, Sun SW. Sequential phases of RGC axonal and somatic injury in EAE mice examined using DTI and OCT. Mult Scler Relat Disord. 2019; 27:315–23. Epub 2018/11/24. https://doi.org/10.1016/j.msard.2018.11.010 PMID: 30469023; PubMed Central PMCID: PMC6392031.

19. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006; 59(3):478–89. Epub 2006/01/05. https://doi.org/10.1002/ana.20736 PMID: 16392116.

20. Castegna A, Palmieri L, Spiera I, Porcelli V, Palmieri F, Fabis-Pedrini MJ, et al. Oxidative stress and reduced glutamate synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis. Neuroscience. 2011; 185:97–105. Epub 2011/05/04. https://doi.org/10.1016/j.neuroscience.2011.04.041 PMID: 21536110.

21. Giannetti P, Politis M, Su P, Keihaninejad S, et al. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis. 2014; 7(1):125. Epub 2019/08/02. https://doi.org/10.1016/j.nbd.2014.01.018 PMID: 24508617.

22. Wu WF, Tan XJ, Dai YB, Krishnan V, Warner M, Gustafsson J. Targeting estrogen receptor β in microglia and T cells to treat experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2013; 110(9):3543–8. Epub 2013/02/13. https://doi.org/10.1073/pnas.1300313110 PMID: 23401502; PubMed Central PMCID: PMC3587193.

23. Howell OW, Rundie JL, Garg A, Komada M, Brophy PJ, Reynolds R. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol. 2010; 69(10):1017–33. Epub 2010/09/15. https://doi.org/10.1097/NEN.0b013e3181f3a5b1 PMID: 20838243; PubMed Central PMCID: PMC3335193.

24. Ljubisavljevic S, Stojanovic I, Pavlovic R, Sokolovic D, Cvetkovic T, et al. Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis. J Neurol Sci. 2012; 318(1–2):106–11. Epub 2012/04/18. https://doi.org/10.1016/j.jns.2012.03.015 PMID: 22507752.

25. Palani CD, Fouda AY, Liu F, Xu Z, Mohamed E, Giri S, et al. Deletion of Arginase 2 Ameliorates Retinal Neurodegeneration in a Mouse Model of Multiple Sclerosis. Mol Neurobiol. 2019; 56(12):8589–602. Epub 2019/07/08. https://doi.org/10.1007/s12035-019-01691-w PMID: 31280447; PubMed Central PMCID: PMC6857799.

26. Davis EJ, Foster TD, Thomas WE. Cellular forms and functions of brain microglia. Brain Res Bull. 1994; 34(1):73–8. Epub 1994/01/01. https://doi.org/10.1016/0361-9230(94)90189-9 PMID: 8193937.

27. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981; 11(10):805–15. Epub 1981/10/01. https://doi.org/10.1002/eji.1830111013 PMID: 7308288.

28. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990; 39(1):151–70. Epub 1990/01/01. https://doi.org/10.1016/0306-4522(90)90229-w PMID: 2089275.

29. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008; 13:453–61. https://doi.org/10.2741/2692 PMID: 17981560.

30. Chinnery HR, McMenamin PG, Dando SJ. Macrophage physiology in the eye. Pflugers Arch. 2017; 469(3–4):501–15. https://doi.org/10.1007/s00424-017-1947-5 PMID: 28233124.

31. Feng L, Puyang Z, Chen H, Liang P, Troy JB, Liu X. Overexpression of Brain-Derived Neurotrophic Factor Protects Large Retinal Ganglion Cells After Optic Nerve Crush in Mice. eNeuro. 2017; 4(1). Epub 2017/01/20. https://doi.org/10.1523/ENEURO.0331-16.2016 PMID: 28101532; PubMed Central PMCID: PMC5240030.

32. Renner M, Stute G, Alzureiqi M, Reinhard J, Wiemann S, Schmid H, et al. Optic Nerve Degeneration after Retinal Ischemia/Reperfusion in a Rodent Model. Front Cell Neurosci. 2017; 11:254. Epub 2017/09/08. https://doi.org/10.3389/fncel.2017.00254 PMID: 28878627; PubMed Central PMCID: PMC5572359.
33. Noristani R, Kuehn S, Stute G, Reinehr S, Stellbogen M, Dick HB, et al. Retinal and Optic Nerve Damage is Associated with Early Glial Responses in an Experimental Autoimmune Glaucoma Model. J Mol Neurosci. 2016; 58(4):470–82. Epub 2016/01/10. https://doi.org/10.1007/s12031-015-0707-2 PMID: 26746422.

34. Alrashdi B, Dawod B, Schampel A, Tacke S, Kuerten S, Marshall JS, et al. Nav1.6 promotes inflammation and neuronal degeneration in a mouse model of multiple sclerosis. J Neuroinflammation. 2019; 16(1):215. Epub 2019/11/15. https://doi.org/10.1186/s12974-019-1622-1 PMID: 31722722; PubMed Central PMCID: PMC6852902.

35. Khan RS, Baumann B, Dine K, Song Y, Dunaief JL, Kim SF, et al. Dexras1 Deletion and Iron Chelation Promote Neuroprotection in Experimental Optic Neuritis. Sci Rep. 2019; 9(1):11664. Epub 2019/08/14. https://doi.org/10.1038/s41598-019-48087-3 PMID: 31406150; PubMed Central PMCID: PMC6690882.

36. Locri F, Cammalleri M, Pini A, Dal Monte M, Rusciano D, Bagnoli P. Further Evidence on Efficacy of Reducing Glutathione and S-Nitrosothiols Levels in Acute Phase of Experimental Demyelination—Pathophysiological Approach and Possible Clinical Relevance. Neurosci. 2016; 58(4):470–82. Epub 2016/01/10. https://doi.org/10.1179/1351000211Y.000000007 PMID: 22277070; PubMed Central PMCID: PMC3279590.

37. Barnett MH, Henderson AP, Prineas JW. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler. 2006; 12(2):121–32. https://doi.org/10.1191/1354631105ms1304rr PMID: 16628145.

38. Su KG, Savino C, Marracci G, Chaudhary P, Yu X, Morris B, et al. Genetic inactivation of the p66 isoform of Sca1 is neuroprotective in a murine model of multiple sclerosis. Eur J Neurosci. 2012; 35(4):562–71. https://doi.org/10.1111/j.1460-9568.2011.07972.x PMID: 22277070; PubMed Central PMCID: PMC3279590.

39. Xiong Y, Cheng S, Wu X, Ren Y, Xie X. Changes of B cell subsets in central pathophysiology of the acute MS lesion. Mult Scler. 2006; 12(2):121–32. https://doi.org/10.1191/1354631105ms1304rr PMID: 16628145.

40. Ljubisavljevic S, Stojanovic I, Pavlovic R, Stojnev S, Stevanovic I, Sokolovic D, et al. The reduced glutathione and S-nitrosothiols levels in acute phase of experimental demyelination—pathophysiological approach and possible clinical relevance. Neuroscience. 2012; 219:175–82. Epub 2012/06/09. https://doi.org/10.1016/j.neuroscience.2012.05.062 PMID: 22677204.

41. Ljubisavljevic S, Stojanovic I, Pavlovic D, Sokolovic D, Stevanovic I. Aminoguanidine and N-acetyl-cysteine suppress oxidative and nitrosative stress in EAE rat brains. Redox Rep. 2011; 16(4):166–72. Epub 2011/09/06. https://doi.org/10.1179/135100211Y.0000000007 PMID: 21888767; PubMed Central PMCID: PMC6837682.

42. Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: A Multifaceted Enzyme Important in Health and Disease. Physiol Rev. 2018; 98(2):641–65. Epub 2018/02/08. https://doi.org/10.1152/physrev.00037.2016 PMID: 29412048; PubMed Central PMCID: PMC5966781.

43. Shosha E, Xu Z, Yokota H, Saul A, Rojas M, Caldwell RW, et al. Arginase 2 promotes neurovascular degeneration during ischemia/reperfusion injury. Cell Death Dis. 2016; 7(11):e2483. Epub 2016/11/25. https://doi.org/10.1038/cddis.2016.295 PMID: 27882947; PubMed Central PMCID: PMC5260867.

44. Narayanan SP, Xu Z, Purtuli N, Sreekumar A, Lemtalsi T, Caldwell RW, et al. Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism. Cell Death Dis. 2014; 5(2):e1075. Epub 2014/02/22. https://doi.org/10.1038/cddis.2014.23 PMID: 24556690; PubMed Central PMCID: PMC3944241.

45. Xu Z, Fouda AY, Lemtalsi T, Shosha E, Rojas M, Liu F, et al. Retinal Neuroprotection From Optic Nerve Trauma by Deletion of Arginase 2. Front Neurosci. 2012; 6:970. Epub 2012/09/01. https://doi.org/10.3389/fnins.2018.00970 PMID: 30618589; PubMed Central PMCID: PMC6306467.

46. Agrawal SM, Yong VW. Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol. 2007; 79:99–126. Epub 2007/05/29. https://doi.org/10.1016/S0074-7742(07)79005-0 PMID: 17531839.

47. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8 (+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000; 192(3):393–404. Epub 2000/08/10. https://doi.org/10.1084/jem.192.3.393 PMID: 10934227; PubMed Central PMCID: PMC2193223.

48. Dong Y, Yong VW. When encephalitogenic T cells collaborate with microglia in multiple sclerosis. Nature Reviews Neurology. 2019; 15(12):704–17. https://doi.org/10.1038/s41585-019-0253-6 PMID: 31527807.

49. Bennett J, Basivreddy J, Kollar A, Biron KE, Reichmann P, Jeffries WA, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol. 2010; 229(1–2):180–91. Epub 2010/09/14. https://doi.org/10.1016/j.jneuroim.2010.08.011 PMID: 20832870.
50. Badawi AH, Kiptoo P, Wang WT, Choi IY, Lee P, Vines CM, et al. Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor. Neuropharmacology. 2012; 62(4):1874–81. Epub 2012/01/03. https://doi.org/10.1016/j.neuropharm.2011.12.013 PMID: 22210333; PubMed Central PMCID: PMC3269550.

51. Gold R, Linnington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006; 129(Pt 8):1953–71. Epub 2006/04/25. https://doi.org/10.1093/brain/awl075 PMID: 16632554.

52. Zhu Y, Zhang L, Lu Q, Gao Y, Cai Y, Sui A, et al. Identification of different macrophage subpopulations with distinct activities in a mouse model of oxygen-induced retinopathy. Int J Mol Med. 2017; 40(2):281–92. https://doi.org/10.3892/ijmm.2017.3022 PMID: 28627621; PubMed Central PMCID: PMC5504985.

53. Zhou Y, Yoshida S, Kubo Y, Yoshimura T, Kobayashi Y, Nakama T, et al. Different distributions of M1 and M2 macrophages in a mouse model of laser-induced choroidal neovascularization. Mol Med Rep. 2017; 15(6):3949–56. https://doi.org/10.3892/mmr.2017.6491 PMID: 28440413; PubMed Central PMCID: PMC5436148.

54. Schmidt A, Streeker JK, Huckle S, Bruckmann NM, Herold M, Mack M, et al. Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke. Stroke. 2017; 48(4):1061–9. Epub 2017/03/16. https://doi.org/10.1161/STROKEAHA.116.015577 PMID: 28292872.

55. Fang M, Yamasaki R, Li G, Masaki K, Yamaguchi H, Fujita A, et al. Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia. Front Immunol. 2018; 9:2588. Epub 2018/11/23. https://doi.org/10.3389/fimmu.2018.02588 PMID: 30464764; PubMed Central PMCID: PMC6234958.

56. Rossetti I, Zambusi L, Finardi A, Bodini A, Provini L, Furlan R, et al. Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018; 323:94–104. Epub 2018/09/11. https://doi.org/10.1016/j.jneuroim.2018.07.005 PMID: 30196840.

57. Xu L, Hilliard B, Carmody RJ, Tsabary G, Shin H, Christianson DW, et al. Arginase and autoimmunity inflammation in the central nervous system. Immunology. 2003; 110(1):141–8. Epub 2003/08/28. https://doi.org/10.1046/j.1365-2567.2003.01713.x PMID: 12941151; PubMed Central PMCID: PMC1783013.

58. Carmody RJ, Hilliard B, Maguschak K, Chodosh LA, Chen YH. Genomic scale profiling of autoimmune inflammation in the central nervous system: the nervous response to inflammation. Journal of Neuroimmunology. 2002; 133(1):95–107. https://doi.org/10.1016/s0165-5728(02)00366-1 PMID: 12446012.

59. Greenhalgh AD, Passos Dos Santos R, Zarruk JG, Salmon CK, Kroner A, David S. Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease. Brain Behav Immun. 2016; 56:61–7. https://doi.org/10.1016/j.bbi.2016.04.013 PMID: 27126514.

60. Melero-Jerez C, Suardiaz M, Lebron-Galan R, Marin-Banasco C, Oliver-Martos B, Machin-Diaz I, et al. The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-beta treatment in a murine model of multiple sclerosis. Neurobiol Dis. 2019; 127:13–31. https://doi.org/10.1016/j.nbd.2019.02.014 PMID: 30798007.

61. Molina-Velazquez V, Cuervo H, Vila-Del Sol V, Ortega MC, Clemente D, de Castro F. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. Brain Pathol. 2011; 21(6):678–91. https://doi.org/10.1111/j.1750-3639.2011.00495.x PMID: 21507122.

62. Brambilla R, Dvoriantchikova G, Barakat D, Ivanov D, Bethea JR, Shestopalov VI. Transgenic inhibition of astroglial NF-κB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis. J Neuroinflammation. 2012; 9:213. Epub 2012/09/12. https://doi.org/10.1186/1742-2094-9-213 PMID: 22963651; PubMed Central PMCID: PMC3490907.

63. Lin TH, Kim JH, Perez-Torres C, Chiang CW, Trinkaus K, Cross AH, et al. Axonal transport rate decreased at the onset of optic neuritis in EAE mice. Neuroimage. 2014; 100:244–53. Epub 2014/06/18. https://doi.org/10.1016/j.neuroimage.2014.06.009 PMID: 24936685; PubMed Central PMCID: PMC4138234.

64. Bignami A, Dahl D, Nguyen BT, Crosby CJ. The fate of axonal debris in Wallerian degeneration of rat optic and sciatic nerves. Electron microscopy and immunofluorescence studies with neurofilament antisera. J Neuropathol Exp Neurol. 1981; 40(5):537–50. Epub 1981/09/01. https://doi.org/10.1097/00005072-19810900-00008 PMID: 7024479.

65. Knöferle J, Koch JC, Ostendorf T, Michel U, Planchamp V, Vutova P, et al. Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A. 2010; 107(13):6064–9. Epub 2010/03/17. https://doi.org/10.1073/pnas.0907974107 PMID: 20231460; PubMed Central PMCID: PMC2851885.
66. Coombs J, van der List D, Wang GY, Chalupa LM. Morphological properties of mouse retinal ganglion cells. Neuroscience. 2006; 140(1):123–36. Epub 2006/04/22. https://doi.org/10.1016/j.neuroscience.2006.02.079 PMID: 16626866.

67. Lin B, Wang SW, Masland RH. Retinal ganglion cell type, size, and spacing can be specified independent of homotypic dendritic contacts. Neuron. 2004; 43(4):475–85. Epub 2004/08/18. https://doi.org/10.1016/j.neuron.2004.08.002 PMID: 15312647.

68. Rodriguez AR, de Sevilla Muller LP, Brecha NC. The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina. J Comp Neurol. 2014; 522(6):1411–43. Epub 2013/12/10. https://doi.org/10.1002/cne.23521 PMID: 24318667; PubMed Central PMCID: PMC3959221.

69. Irvine KA, Blakemore WF. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57Bl/6 mice. J Neuroimmunol. 2006; 175(1–2):69–76. Epub 2006/04/22. https://doi.org/10.1016/j.jneuroim.2006.03.002 PMID: 16626812.

70. Redondo J, Kemp K, Hares K, Rice C, Scolding N, Wilkins A. Purkinje cell pathology and loss in multiple sclerosis cerebellum. Brain Pathol. 2015; 25(6):692–700. Epub 2014/11/21. https://doi.org/10.1111/bpa.12230 PMID: 25411024; PubMed Central PMCID: PMC4780274.

71. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001; 50(2):169–80. Epub 2001/08/17. https://doi.org/10.1002/ana.1077 PMID: 11506399.

72. Bernardes D, Brambilla R, Bracci-Ricard V, Karmally S, Dellarole A, Carvalho-Tavares J, et al. Prior regular exercise improves clinical outcome and reduces demyelination and axonal injury in experimental autoimmune encephalomyelitis. J Neurochem. 2016; 136 Suppl 1:63–73. Epub 2015/09/15. https://doi.org/10.1111/jnc.13354 PMID: 26364732.

73. Stojic A, Bojcevski J, Williams SK, Diem R, Fairless R. Early Nodal and Paranodal Disruption in Autoimmune Optic Neuritis. J Neuropathol Exp Neurol. 2018; 77(5):361–73. Epub 2018/02/15. https://doi.org/10.1033/jnep.111 PMID: 2944299.

74. Deng K, He H, Qiu J, Lorber B, Bryson JB, Filbin MT. Increased synthesis of spermidine as a result of arginase I expression without alteration in arginase I expression attenuates experimental autoimmune encephalomyelitis in mice. Immunology. 2018; 155(1):85–98. Epub 2018/03/27. https://doi.org/10.1111/imn.12926 PMID: 29574762; PubMed Central PMCID: PMC6099175.

75. Choudry M, Tang X, Santorin T, Wasnik S, Xiao J, Xing W, et al. Deficient arginase II expression without alteration in arginase I expression attenuated experimental autoimmune encephalomyelitis in mice. J Neuroimmunol. 2006; 175(1–2):69–76. Epub 2006/04/22. https://doi.org/10.1016/j.jneuroim.2006.03.002 PMID: 16626812.

76. John GR, Lee SC, Brosnan CF. Cytokines: powerful regulators of glial cell activation. Neuroscientist. 2003; 9(1):10–22. Epub 2003/02/13. https://doi.org/10.1177/1073858402239587 PMID: 12580336.

77. Gimsa U, ØRen A, Pandiyan P, Teichmann D, Bechmann I, Nitsch R, et al. Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyte-induced upregulation of CTLA-4 (CD152). J Mol Med (Berl). 2004; 82(3):9545–52. Epub 2009/07/31. https://doi.org/10.1002/jnm.1175-09.2009 PMID: 19641117; PubMed Central PMCID: PMC6665538.

78. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001; 50(2):169–80. Epub 2001/08/17. https://doi.org/10.1002/ana.1077 PMID: 11506399.

79. Coombs J, van der List D, Wang GY, Chalupa LM. Morphological properties of mouse retinal ganglion cells. Neuroscience. 2006; 140(1):123–36. Epub 2006/04/22. https://doi.org/10.1016/j.neuroscience.2006.02.079 PMID: 16626866.

80. Veremeyko T, Yung AWY, Dukhinova M, Kuznetsova IS, Pomyskin I, Lyundup A, et al. Cyclic AMP Pathway Suppress Autoimmune Neuroinflammation by Inhibiting Functions of Encephalitogenic CD4 T Cells and Enhancing M2 Macrophage Polarization at the Site of Inflammation. Front Immunol. 2018; 9:50. https://doi.org/10.3389/fimmu.2018.00050 PMID: 29422898; PubMed Central PMCID: PMC5789911.

81. Watson B, Pramanik G, Hess M, Klein M, Luessi F, Dormair K, et al. Increase of Alternatively Activated Antigen Presenting Cells in Active Experimental Autoimmune Encephalomyelitis. J Neuroimmune Pharmacol. 2016; 11(4):721–32. https://doi.org/10.1007/s11481-016-9696-3 PMID: 27423192.

82. Moliné-Velázquez V, Ortega MC, Vila del Sol V, Melero-Jerez C, de Castro F, Clemente D. The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability. Neurobiology of disease. 2014; 67:149–64. Epub 2014/04/09. https://doi.org/10.1016/j.nbd.2014.03.017 PMID: 24709559.

83. Melero-Jerez C, Alonso-Gómez A, Moñivas E, Lebrón-Galán R, Machín-Díaz I, de Castro F, et al. The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis. Neurobiology of disease. 2020; 140:104869. https://doi.org/10.1016/j.nbd.2020.104869 PMID: 32278882.